Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine

Drug and Alcohol Dependence

Volumn 118, Issue 1, 2011, Pages 40-47

  Matsumoto, Rae R ^a,b   Li, Su Min ^c   Katz, Jonathan L ^c   Fantegrossi, William E ^d,e   Coop, Andrew ^f  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cocaine; Conditioned place preference; Drug discrimination; Locomotor activity; Self administration; Sigma receptors

Indexed keywords

1 (2 PHENETHYL)PIPERIDINE OXALATE; AC 927; COCAINE; OPIATE AGONIST; SIGMA OPIATE RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONDITIONING; CONTROLLED STUDY; CONVULSION; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; LETHALITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIMATE; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE;

ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; LIGANDS; MACACA MULATTA; MALE; MICE; MODELS, ANIMAL; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; OXALIC ACIDS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; SEIZURES; SELF ADMINISTRATION;

ANIMALIA; MUS; PRIMATES; RATTUS;

EID: 80052290279     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.02.017     Document Type: Article

References (52)

1. Aydar E., Palmer C.P., Klyachko V.A., Jackson M.B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34:399-410.
2. Bastianetto S., Rouqier L., Perrault G., Sanger D.J. DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways. Neuropharmacology 1995, 34:281-287.
3. Brackett R.L., Pouw B., Blyden J.F., Nour M., Matsumoto R.R. Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology 2000, 39:407-418.
4. 2 Receptors up regulate changes in sphingolipid levels in breast tumor cells. Eur. J. Pharmacol. 2002, 443:207-209.
5. Engel S.R., Purdy R.H., Grant K.A. Characterization of discriminative stimulus effects of the neuroactive steroid pregnanolone. J. Pharmacol. Exp. Ther. 2001, 297:489-495.
6. Fantegrossi W.E., Winger G., Wood J.H., Woolverton W.L., Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend. 2005, 77:161-168.
7. Fantegrossi W.E., Woolverton W.L., Kilbourn M., Sherman P., Yuan J., Hatzidimitriou G., Ricaurte G.A., Woods J.H., Winger G. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 2004, 29:1270-1281.
8. Finney D.J. Statistical Method in Biological Assay 1964, Hafner, New York. 2nd ed.
9. 2 Receptors are specially localized to lipid rafts in rat liver membranes. Eur. J. Pharmacol. 2004, 493:19-28.
10. Goldstein S.R., Matsumoto R.R., Thompson T.L., Patrick R.L., Bowen W.D., Walker J.M. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 1989, 4:254-258.
11. Gudelsky G.A. Effects of σ receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur. J. Pharmacol. 1995, 286:223-228.
12. Guitart X., Codony X., Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 2004, 174:301-319.
13. 3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci. 1986, 6:1757-1770.
14. 2+ signaling and cell survival. Cell 2007, 131:596-610.
15. Hellewell S.B., Bowen W.D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benxomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 1990, 527:244-253.
16. Hiranita T., Soto P.L., Tanda G., Katz J.L. Reinforcing effects of σ-receptor agonists in rats trained to self-administer cocaine. J. Pharmacol. Exp. Ther. 2010, 332:515-524.
17. 1 receptors. Nucl. Med. Biol. 2000, 27:255-261.
18. Lason W. Neurochemical and pharmacological aspects of cocaine-induced seizures. Pol. J. Pharmacol. 2001, 53:57-60.
19. Li S.M., Campbell B.L., Katz J.L. Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J. Pharmacol. Exp. Ther. 2006, 317:1088-1096.
20. Liu Y., Chen G.D., Lerner M.R., Brackett D.J., Matsumoto R.R. Cocaine up-regulates fra-2 and σ-1 receptor gene and protein expression in brain regions involved in addiction and reward. J. Pharmacol. Exp. Ther. 2005, 314:770-779.
21. 1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J. Pharmacol. Exp. Ther. 2008, 327:187-195.
22. Maeda D.Y., Williams W., Kim W.E., Thatcher L.N., Bowen W.D., Coop A. N-Arylalkylpiperidines as high affinity sigma-1 and sigma-2 receptor ligands: phenylpropylamines as potential leads for sigma-2 agents. Bioorg. Med. Chem. Lett. 2002, 12:497-500.
23. Martina M., Turcotte M.-E.B., Halman S., Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J. Physiol. 2007, 578:143-157.
24. Matsumoto R.R. Targeting sigma receptors: novel medication development for drug abuse and addiction. Exp. Rev. Clin. Pharmacol. 2009, 2:351-358.
25. Matsumoto R.R., Liu Y., Lerner M., Howard E.W., Brackett D.J. Sigma receptors: potential medications development target for anti-cocaine agents. Eur. J. Pharmacol. 2003, 469:1-12.
26. Matsumoto R.R., Hewett K.L., Pouw B., Bowen W.D., Husbands S.M., Cao J.J., Newman A.H. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 2001, 41:878-886.
27. 1 receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 2001, 419:163-174.
28. Matsumoto R.R., McCracken K.A., Pouw B., Zhang Y., Bowen W.D. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002, 42:1043-1055.
29. Matsumoto R.R., Shaikh J., Wilson L.L., Vedam S., Coop A. Attenuation of methamphetamine-induced effects through antagonism of sigma receptors: evidence from in vivo and in vitro studies. Eur. Neuropsychopharmacol. 2008, 18:871-881.
30. McCracken K.A., Bowen W.D., Matsumoto R.R. Novel σ ligands attenuate the locomotor stimulatory effects of cocaine. Eur. J. Pharmacol. 1999, 365:35-38.
31. McCracken K.A., Bowen W.D., de Costa B.R., Matsumoto R.R. Two novel sigma ligands, BD1047 and LR172, attenuate cocaine-induced convulsions and locomotor activity. Eur. J. Pharmacol. 1999, 370:225-232.
32. Menkel M., Terry P., Pontecorvo M., Katz J.L., Witkin J.M. Selective σ ligands block stimulant effects of cocaine. Eur. J. Pharmacol. 1991, 201:251-252.
33. 1 receptor agonists in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 2003, 307:705-712.
34. 1 receptor antagonist NE-100 attenuates the discriminative stimulus effects of ketamine in rats. Addict. Biol. 2001, 6:373-376.
35. 1 receptor-mediated effects of cocaine. Proc. Natl. Acad. Sci. 2010, 107:18676-18681.
36. Novakova M., Ela C., Barg J., Vogel Z., Hasin Y., Eilam Y. Iontropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur. J. Pharmacol. 1995, 286:19-30.
37. 1) receptor-related neuroactive steroids modulate cocaine-induced reward. J. Neurosci. 2003, 23:3572-3576.
38. 1 receptor in the cocaine-induced conditioned place preference. NeuroReport 2000, 11:2885-2888.
39. 1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacology 2004, 175:154-162.
40. 1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002, 26:444-455.
41. Sharkey J., Glen K.A., Wolfe S., Kuhar M.J. Cocaine binding at σ receptors. Eur. J. Pharmacol. 1988, 149:171-174.
42. Slifer B.L., Balster R.L. Reinforcing properties of stereoisomers of the putative sigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. J. Pharmacol. Exp. Ther. 1983, 225:522-528.
43. Snedecor G.W., Cochran W.G. Statistical Methods 1967, Iowa State University Press, Ames, IA, pp. 135-171. 6th ed.
44. Steinfels G.F., Alberici G.P., Tam S.W., Cook L. Biochemical, behavioral, and electrophysiological actions of the selective sigma receptor ligand (+)-pentazocine. Neuropsychopharmacology 1988, 1:321-327.
45. Su T.P., Hayashi T., Maurice T., Buch S., Ruoho A.E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 2010, 31:557-566.
46. Tsai S.Y., Hayashi T., Mori T., Su T.P. Sigma-1 receptor chaperones and diseases. Cent. Nerv. Syst. Agents Med. Chem. 2009, 9:184-189.
47. Uhl G.R., Hall F.S., Sora I. Cocaine, reward, movement and monoamine transporters. Mol. Psychiatry 2002, 7:21-26.
48. Ujike H., Kuroda S., Otsuke S. σ Receptor antagonists block the development of sensitization to cocaine. Eur. J. Pharmacol. 1996, 296:123-128.
49. 3H]dopamine release from rat pheochromocytoma (PC12) cells by sigma type 2 receptors. J. Pharmacol. Exp. Ther. 1999, 289:278-284.
50. Witkin J.M., Gasior M., Heifets B., Tortella F.C. Anticonvulsant efficacy of N-methyl-d-aspartate antagonists against convulsions induced by cocaine. J. Pharmacol. Exp. Ther. 1999, 289:703-711.
51. Witkin J.M., Terry P., Menkel M., Hickey P., Pontecorvo M., Ferkany J., Katz J.L. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy)-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J. Pharmacol. Exp. Ther. 1993, 266. 473-382.
52. Xu Y.T., Kaushal N., Shaikh J., Wilson L.L., Mesangeau C., McCurdy C.R., Matsumoto R.R. A novel substituted piperazine, 3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole-2(3H)-thione (CM156), attenuate the stimulant and toxic effects of cocaine in mice. J. Pharmacol. Exp. Ther. 2010, 333:491-500.